Evaluation of the Lifetime Benefits of Metformin and SGLT2 Inhibitors in Type 2 Diabetes Mellitus Patients with Cardiovascular Disease: A Systematic Review and Two-Stage Meta-Analysis-Reference-Cited by-同舟云学术

Evaluation of the Lifetime Benefits of Metformin and SGLT2 Inhibitors in Type 2 Diabetes Mellitus Patients with Cardiovascular Disease: A Systematic Review and Two-Stage Meta-Analysis

Published:2024-04-08 Issue:3 Volume:24 Page:371-383
ISSN:1175-3277
Container-title:American Journal of Cardiovascular Drugs
language:en
Short-container-title:Am J Cardiovasc Drugs

Author:

Wong Hon Jen,Lin Norman H.,Teo Yao Neng,Syn Nicholas L.,Teo Yao Hao,Sia Ching-Hui^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40256-024-00640-w.pdf

Reference51 articles.

1. Sun H, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. https://doi.org/10.1016/j.diabres.2021.109119.

2. Stam-Slob MC, et al. Effect of type 2 diabetes on recurrent major cardiovascular events for patients with symptomatic vascular disease at different locations. Diabetes Care. 2015;38(8):1528–35. https://doi.org/10.2337/dc14-2900.

3. Shin H, et al. Trends in first-line glucose-lowering drug use in adults with type 2 diabetes in light of emerging evidence for SGLT-2i and GLP-1RA. Diabetes Care. 2021;44(8):1774–82. https://doi.org/10.2337/dc20-2926.

4. Moran GM, et al. Type 2 diabetes: summary of updated NICE guidance. BMJ. 2022;377:o775. https://doi.org/10.1136/bmj.o775.

5. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022. Diabetes Care, 2022; 45(Suppl 1):S125-S143. doi:https://doi.org/10.2337/dc22-S009